Unknown Analyst (on behalf of Umer Raffat)'s questions to Atea Pharmaceuticals Inc (AVIR) leadership • Q3 2024
Question
An analyst from Evercore ISI inquired if the pharmacokinetic (PK) profile, particularly the half-life, of the drug components changed in the fixed-dose combination. They also asked if the Phase III trial would use the same dose as Phase II and if it would primarily enroll patients outside the U.S.
Answer
CEO Dr. Jean-Pierre Sommadossi confirmed there was no change in the PK profile, drug exposure, or half-life for either drug in the combination. Chief Medical Officer Dr. Arantxa Horga affirmed the dose will remain the same but will be administered as a new fixed-dose combination tablet. She clarified that Phase III will include a significant number of U.S. sites, with Dr. Sommadossi adding they anticipate over 100 sites in the U.S. alone.